Aegerion Pharmaceuticals Price Target Raised to $102.00 at Jefferies Group (AEGR)
Equities research analysts at Jefferies Group hoisted their price objective on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) from $92.00 to $102.00 in a research note issued to investors on Thursday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target points to a potential upside of 23.16% from the stock’s previous close.
AEGR has been the subject of a number of other recent research reports. Analysts at Cowen and Company raised their price target on shares of Aegerion Pharmaceuticals to $105.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at FBR & Co. initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating and a $111.00 price target on the stock. Eleven equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $92.58.
Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 2.85% during mid-day trading on Thursday, hitting $82.82. The stock had a trading volume of 832,979 shares. Aegerion Pharmaceuticals has a one year low of $13.33 and a one year high of $101.00. The stock’s 50-day moving average is $86.71 and its 200-day moving average is $73.8. The company’s market cap is $2.399 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, October 29th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.07. The company had revenue of $16.30 million for the quarter, compared to the consensus estimate of $13.07 million. Aegerion Pharmaceuticals’s revenue was up 1629900.0% compared to the same quarter last year. Analysts expect that Aegerion Pharmaceuticals will post $-2.10 EPS for the current fiscal year.
In other Aegerion Pharmaceuticals news, CEO Marc D. Beer sold 40,000 shares of the stock on the open market in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $87.79, for a total transaction of $3,511,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.